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532 The Journal of Thoracic and CardioBackground: Chronic calcium channel blocker therapy has traditionally been con-
sidered necessary in patients carrying a radial artery graft, even in the absence of
objective data to support it. This report was conceived to evaluate the angiographic
and clinical effects of calcium channel blocker therapy during the first postoperative
year.
Patients and Results: A total of 100 consecutive patients who received a radial
artery graft at our institution were randomly assigned to receive (n  53) or not
receive (n  47) calcium channel blocker therapy with oral diltiazem 120 mg/daily
started in the early postoperative period. At 1-year follow-up, all patients were
reassessed clinically and by Tl201 myocardial scintigraphy, and 83 of them under-
went control angiography. In 12 cases we also evaluated the response of the radial
artery to the endovascular infusion of serotonin. No difference in terms of clinical
outcome, scintigraphic results, and patency rate was found between patients who
received or did not receive calcium channel blocker therapy. Endovascular serotonin
infusion evoked an evident spastic reaction of radial artery grafts, not attenuated by
calcium channel blocker therapy.
Conclusion: Calcium channel blocker therapy started immediately after surgery and
continued for the first postoperative year does not affect radial artery graft patency
and clinical and scintigraphic outcomes. On the basis of these data, the prophylactic
use of calcium channel blocker therapy in patients with radial artery grafts seems
unsubstantiated.
Since the reintroduction of radial artery (RA) grafts in coronarysurgery in the mid-1990s, a chronic antispastic therapy (usuallyusing calcium channel blockers) has traditionally been considerednecessary.However, to date only scant objective data on the optimumduration of postoperative chronic calcium channel blocker therapy
(CCBT) have been published, so the modalities of the antispastic therapy are
actually empirically established by the single centers.
In a previous study we showed that beyond the first postoperative year CCBT
does not ensure substantial advantages in terms of both clinical results and RA
graft patency.1 However, concerns still exist about the role of CCBT in the
initial period after surgery, when the spastic tendency of the RA is thought to be
maximal.2
This report was conceived to evaluate the angiographic and clinical effects of
CCBT during the first postoperative year.
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Patient Population
Our experience with RA grafting started in January 1993; since the
beginning of our series, the antispastic therapy consisted of oral
diltiazem (120 mg/daily) started in the early postoperative period.3
The early, midterm, and long-term clinical and angiographic
results, as well as the early and midterm alterations of the forearm
circulation and the midterm vasodilatory profile of the RA grafts,
have been the object of previous publications.1-7
The present report is intended to describe the clinical and
angiographic effect of CCBT in the first postoperative year.
For this purpose, 100 consecutive patients who received an RA
graft at our institution between January 2000 and March 2001 were
randomly assigned to receive (n  53) or not receive (n  47)
CCBT started in the early postoperative period.
In patients assigned to receive CCBT, oral diltiazem (120
mg/daily) was started the day of extubation (the first postoperative
day in 49 cases and the following day in the remaining cases); no
intravenous diltiazem was used in this series. Patients assigned to
the no-CCBT group did not receive CCBT in any form during the
hospital stay and follow-up period.
Follow-up
After 6 months and 1 year all cases were submitted to clinical and
scintigraphic control; 83 of them (42 from the CCBT group and 41
from the no-CCBT group) also agreed to be submitted to 1-year
angiographic control.
Graft morphology was graded according to the 4 grades scale in
use at our institution2,7: perfectly patent graft, patent graft with
TABLE 1. Preoperative characteristics of patients of the
two groups
CCBT
group
No-CCBT
group
P
value
No. of cases 53 47 —
Mean age (y) 63.8  4.6 63.2  3.5 .46
Male/female 38/15 32/15 .86
Cardiac risk factors
Diabetes 11 10 .89
Smoking 23 21 .94
Dyslipidemia 19 22 .36
Hypertension 12 10 .93
Previous myocardial infarction 29 25 .96
Three-vessel disease 41 39 .65
Left-main disease 2 1 1.00*
Radial artery target vessel
OM 25 21 .96
PDA 15 13 .65
RCA 11 12 .74
Diag 2 1 1.00*
CCBT, Calcium channel blocker therapy; Diag, diagonal branch; OM, ob-
tuse marginal branch; PDA, posterior descending artery; RCA, right coro-
nary artery.
*Two-tailed exact Fisher t test.irregularities, stringed graft, and occluded graft.
The Journal of ThoraciAll angiograms were reviewed blindly by 2 expert observers. In
case of disagreement, a third external blinded review was re-
quested.
Moreover, to verify the effect of CCBT therapy on the spastic
attitude of the RA grafts, we evaluated the response of the RA to
the endovascular infusion of serotonin in 12 patients submitted to
angiography after a previously described method.6
Serotonin hydrochloride 105 mol/L (ICN Pharmaceuticals
Inc, Costa Mesa, Calif) was selectively injected into the graft at a
rate of 3 mL/min for 3 minutes; at the end of the serotonin
challenge 2 mg of isosorbide dinitrate were injected into the
conduit.
Drug infusion was always performed under electrocardiogra-
phy and invasive blood pressure monitoring.
At the end of each step of the protocol a cine run was per-
formed, keeping a fixed angiographic view.
Digital angiograms were then analyzed using computerized
quantitative angiography (Medis, Neuen, The Netherlands).
Statistical Analysis
Results are expressed as mean value  SD. Statistical analysis
comparing 2 groups was performed with parametric or nonpara-
metric tests for independent samples (Student t test and Mann-
Whitney U test for continuous or ordinal data, respectively),
whereas 2 or 2-tailed Fisher exact tests were used to compare
nominal data of the 2 groups. Yates correction was applied when
required (Statistical Package for the Social Science Program, SPSS
Inc, Chicago, Ill).
Results
The mean preoperative clinical and angiographic character-
istics of patients of the 2 groups are summarized in Table 1;
the 2 groups were similar with regard to all the examined
variables.
Follow-up was 100% complete, and mean follow-up
time was 11.8  0.5 months for patients who received
CCBT and 11.9  0.3 for patients who did not receive
CCBT (P  .23).
No patients died during the follow-up. As depicted in
TABLE 2. One-year clinical and scintigraphic results in the
two groups of patients
CCBT
group
No-CCBT
group
P
value
No. of cases 53 47 —
Mean follow-up (mo) 11.8 0.5 11.9 0.3 .23
Death 0 0 —
Angina recurrence 1 0 1.00*
Scintigraphic evidence
of residual ischemia
2 1 1.00*
RA-related residual
ischemia
1 0 1.00*
RA, Radial artery; CCBT, calcium channel blocker therapy.
*Two-tailed exact Fisher t test.Table 2, symptomatic angina was reported by only 1 patient
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tigraphy demonstrated inducible ischemia in 3 cases includ-
ing the symptomatic one; 2 of these cases were from the
CCBT series, and 1 was from the control group (P  .91).
All of the patients with angina or scintigraphic evidence of
ischemia recurrence were submitted to re-angiography; in
only 1 case (from the CCBT group; P  .95) an RA
malfunction (anastomotic stenosis) was the cause for the
ischemia recurrence.
One-year angiography was performed in 83 patients (42
of the CCBT group and 41 of the no-CCBT group). The
angiographic results are summarized in Table 3. No differ-
ences in terms of both patency and perfect patency rates
were found between patients who received or did not re-
ceive CCBT.
Endovascular serotonin infusion evoked an evident spas-
tic reaction of RA grafts, not significantly attenuated by
CCBT (Table 4).
Discussion
Since the early day of its reintroduction in coronary surgery,
the RA propensity for vasospasm has been worrisome.
In fact, in contrast with almost all conduits used for
surgical myocardial revascularization and in particular with
the gold-standard internal thoracic artery, the RA has a thick
muscular wall and only limited amount of elastic tissue in
its media.8 This abundant muscular component is the ana-
tomic background of the hyperspastic attitude of the artery
that has been well documented both in vivo and in vitro. In
a classic organ-bath study, Chardigny and colleagues9 re-
ported that the contractile response elicited on RA rings by
a variety of vasoconstricting stimuli is markedly superior to
that exhibited by both the internal thoracic artery and gas-
troepiploic artery, and our group confirmed this finding in
vivo.6 Furthermore, almost all series of early angiographic
control of RA grafts reported cases of catheter-induced
artery spasm.10,11
For this reason, the necessity for pharmacologic inter-
vention to prevent RA spasm when this artery is used as a
TABLE 3. One-year angiographic results in the two groups
of patients
CCBT
group
No-CCBT
group
P
value
No. of cases 42 41 —
Perfect RA 40 40 1.00*
Stringed RA 1 0 1.00*
Irregular RA 1 0 1.00*
Occluded RA 0 1 1.00*
RA, Radial artery; CCBT, calcium channel blocker therapy.
*Two-tailed exact Fisher t test.coronary artery bypass conduit has been emphasized by
534 The Journal of Thoracic and Cardiovascular Surgery ● Marmany authors, and the good patency rates obtained in the
current era (opposed to the alarming incidence of graft
failure in the 1970s) are often explained on the basis of the
systematic adoption of vasodilating agents.
However, no convincing clinical evidence on the opti-
mum modalities and length of the antispastic therapy is
actually available, and the type of drug and duration of the
treatment are usually established on an empiric basis by the
single authors.
In a previous study, we showed how beyond the first
postoperative year CCBT does not ensure substantial ad-
vantages in terms of both clinical results and RA graft
patency.1 These data are possibly explainable on the basis of
the described morpho-functional remodeling of RA grafts
that, in the years after surgery, tend to lose their peculiar
hyperreactivity and assume a vasoactive profile more sim-
ilar to that of an elastic-walled artery.7
However, the role of CCBT in the early postoperative
period, when RA spastic tendency is thought to be maxi-
mal,2 has yet to be clarified, and its use remains routine in
many centers.
The present study protocol was designed with the aim of
providing objective data on the clinical, scintigraphic, and
angiographic effects of CCBT in the months immediately
after surgery. Our results show how the adoption of calcium
channel blockers does not lead to significant benefits in
terms of clinical and scintigraphic results and RA angio-
graphic status.
Furthermore, data derived from the subset of patients sub-
mitted to endovascular serotonin challenge testifies how CCBT
had no effect on the early vasoreactive profile of the RA.
On the basis of our data, the role and efficacy of CCBT
seems at least debatable.
A possible explanation for these findings is the inappro-
priateness of diltiazem to prevent RA graft spasm. In recent
years several authors have suggested the poor efficacy of
diltiazem on the RA and suggested the use of different
vasodilators (including nitroglycerin, isosorbide dinitrate,
TABLE 4. One-year radial artery response to endovascular
serotonin infusion in the two groups of patients
Continued
group
Suspended
group
P
value
No. of cases 6 6 —
Baseline RA diameter
(mm)
2.10 0.10 2.11 0.10 .86
RA diameter after
serotonin (mm)
1.69 0.32 1.70 0.31 .95
Mean diameter
reduction (mm)
0.41 0.22 0.41 0.21 .99
RA, Radial artery.nicorandil, nifedipine, verapamil, and amlodipine)12-16; al-
ch 2005
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or had a limited follow-up period, the research of the ideal
antispastic drug for RA grafts seems worthwhile in view of
the growing use of this artery in coronary surgery and the
lack of scientific data to support the use of diltiazem.
In conclusion, our data provide substantial evidence that
CCBT with oral diltiazem 120 mg/daily started immediately
after surgery and continued for the first postoperative year
does not affect RA graft patency and clinical and scinti-
graphic outcomes.
On the basis of these data, the prophylactic use of dilti-
azem in patients with RA grafts seems unsubstantiated.
The more appropriate antispastic drug for patients with
RA grafts and, more in general, the opportunity of adopting
a vasodilating therapy in case of RA grafting should be
further investigated.
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